Full Text Journal Articles by
Author Myron E Schwartz

Advertisement

Find full text journal articles






Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply.

Thomas U Marron, Myron E Schwartz, Elizabeth Miller, Pradeep Thanigaimani, Israel Lowy, Gavin Thurston, Miriam Merad,

Lancet Gastroenterol Hepatol (The lancet. Gastroenterology & hepatology)
[2022, 7(6):505]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.

Thomas U Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Stephen C Ward, Zhen Zhao, Joel Kim, Paul Kennedy, Ganesh Gunasekaran, Parissa Tabrizian, Deborah Doroshow, Meredith Legg, Ashley Hammad, Assaf Magen, Alice O Kamphorst, Muhammed Shareef, Namita T Gupta, Raquel Deering, Wei Wang, Fang Wang, Pradeep Thanigaimani, Jayakumar Mani, Leanna Troncoso, Alexandra Tabachnikova, Christie Chang, Guray Akturk, Mark Buckup, Steven Hamel, Giorgio Ioannou, Clotilde Hennequin, Hajra Jamal, Haley Brown, Antoinette Bonaccorso, Daniel Labow, Umut Sarpel, Talia Rosenbloom, Max W Sung, Baijun Kou, Siyu Li, Vladimir Jankovic, Nicola James, Sara C Hamon, Hung Kam Cheung, Jennifer S Sims, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Bachir Taouli, Myron E Schwartz, Miriam Merad,

<h4>Background</h4>Surgical resection of early stage hepatocellular carcinoma is standard clinical practice; however, most tumours recur despite surgery, and no perioperative intervention has shown a survival benefit. Neoadjuvant immunotherapy has induced pathological responses in multiple tumour types and might decrease the risk of postoperative recurrence in hepatocellular carcinoma. We aimed to ... Read more >>

Lancet Gastroenterol Hepatol (The lancet. Gastroenterology & hepatology)
[2022, 7(3):219-229]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

0.5849 s